Compare AVAH & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVAH | PHVS |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2021 | 2021 |
| Metric | AVAH | PHVS |
|---|---|---|
| Price | $9.12 | $25.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | $10.19 | ★ $39.44 |
| AVG Volume (30 Days) | ★ 1.0M | 518.2K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $2,290,591,000.00 | N/A |
| Revenue This Year | $20.08 | N/A |
| Revenue Next Year | $6.99 | N/A |
| P/E Ratio | $24.70 | ★ N/A |
| Revenue Growth | ★ 15.48 | N/A |
| 52 Week Low | $3.67 | $11.51 |
| 52 Week High | $10.32 | $29.80 |
| Indicator | AVAH | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 52.84 | 54.34 |
| Support Level | $8.71 | $23.79 |
| Resistance Level | $9.35 | $25.44 |
| Average True Range (ATR) | 0.30 | 1.91 |
| MACD | -0.00 | -0.17 |
| Stochastic Oscillator | 48.26 | 41.22 |
Aveanna Healthcare Holdings Inc is a diversified home care platform that provides care to medically complex, high-cost patient populations. It directly addresses the pressing challenges facing the U.S. healthcare system by providing safe, high-quality care in the home. The firm provides its services through three segments: Private Duty Services (PDS); Home Health & Hospice (HHH); and Medical Solutions (MS). Private Duty Services include private duty nursing (PDN) and pediatric therapy services. Revenue is derived from pediatric healthcare services provided to patients including private duty nursing and therapy services, adult home health and hospice services (collectively patient revenue) and from the delivery of enteral nutrition and other products to patients.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.